Side-by-side comparison
Regeneron Pharmaceuticals vs Vertex Pharmaceuticals
As of Sep 25, 2026, P/E is 19.5x for Regeneron Pharmaceuticals vs 30.6x for Vertex Pharmaceuticals; P/S is 4.8x for Regeneron Pharmaceuticals vs 10.6x for Vertex Pharmaceuticals; revenue growth is 9.3% for Regeneron Pharmaceuticals vs 10.2% for Vertex Pharmaceuticals; operating margin is 24.7% for Regeneron Pharmaceuticals vs 38.0% for Vertex Pharmaceuticals.
Key metrics
| Metric | REGN | VRTX |
|---|---|---|
| Price | $788.04 | $526.19 |
| Market cap | $74.04B | $133.37B |
| P/E | 19.5x (#1) | 30.6x (#2) |
| P/S | 4.8x (#1) | 10.6x (#2) |
| Revenue growth | 9.3% (#2) | 10.2% (#1) |
| Operating margin | 24.7% (#2) | 38.0% (#1) |
| Net margin | 27.9% (#2) | 35.0% (#1) |
| Debt / equity | 0.06 (#2) | 0.01 (#1) |
| 1-year return | +39.7% (#1) | +36.4% (#2) |
| Research score | 71/100 (#2) | 76/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Regeneron Pharmaceuticals, Inc. (REGN) — Biotechnology
- Vertex Pharmaceuticals Incorporated (VRTX) — Biotechnology